// App-Quantinova.ai

4012 : Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

Researchers

Presenter

  • Anthony B. El-Khoueiry

Principal Investigators

  • Bruno Sangro

  • Thomas Cheung Yau

  • Todd S. Crocenzi

  • Theodore Hobart Welling

  • Winnie Yeo

  • Akhil Chopra

  • Jeffrey Anderson

  • Christine Marie Dela Cruz

  • Lixin Lang

  • Jaclyn Neely

  • Ignacio Melero

Medical Centers

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Clinica Universidad de Navarra, Pamplona, Spain

  • University of Hong Kong, Hong Kong, China

  • Providence Cancer Center, Portland, OR

  • University of Michigan, Ann Arbor, MI

  • Johns Hopkins Singapore International Medical Centre, Singapore, Singapore

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

  • Spain

  • China

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Hepatitis C

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • Unknown

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01658878

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved